JP2016209599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016209599A5 JP2016209599A5 JP2016101062A JP2016101062A JP2016209599A5 JP 2016209599 A5 JP2016209599 A5 JP 2016209599A5 JP 2016101062 A JP2016101062 A JP 2016101062A JP 2016101062 A JP2016101062 A JP 2016101062A JP 2016209599 A5 JP2016209599 A5 JP 2016209599A5
- Authority
- JP
- Japan
- Prior art keywords
- bmp
- bone cement
- flowable
- calcium phosphate
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002639 bone cement Substances 0.000 claims 29
- 239000000126 substance Substances 0.000 claims 20
- 230000009969 flowable effect Effects 0.000 claims 19
- 239000001506 calcium phosphate Substances 0.000 claims 17
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 16
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 15
- 235000011010 calcium phosphates Nutrition 0.000 claims 15
- 239000000463 material Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 5
- -1 silk Substances 0.000 claims 5
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000000853 adhesive Substances 0.000 claims 4
- 230000001070 adhesive effect Effects 0.000 claims 4
- 239000013060 biological fluid Substances 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 230000002188 osteogenic effect Effects 0.000 claims 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 2
- 108010059616 Activins Proteins 0.000 claims 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 2
- 208000006386 Bone Resorption Diseases 0.000 claims 2
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims 2
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 claims 2
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 2
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 claims 2
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims 2
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 claims 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 2
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 claims 2
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims 2
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 claims 2
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 2
- 102000002746 Inhibins Human genes 0.000 claims 2
- 108010004250 Inhibins Proteins 0.000 claims 2
- 102000011782 Keratins Human genes 0.000 claims 2
- 108010076876 Keratins Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000000488 activin Substances 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940124575 antispasmodic agent Drugs 0.000 claims 2
- 229910052586 apatite Inorganic materials 0.000 claims 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000012503 blood component Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000008468 bone growth Effects 0.000 claims 2
- 210000002805 bone matrix Anatomy 0.000 claims 2
- 230000024279 bone resorption Effects 0.000 claims 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229960005188 collagen Drugs 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229960002442 glucosamine Drugs 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- 239000003966 growth inhibitor Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000893 inhibin Substances 0.000 claims 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 229940035363 muscle relaxants Drugs 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 235000003170 nutritional factors Nutrition 0.000 claims 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229960002901 sodium glycerophosphate Drugs 0.000 claims 2
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 101100165563 Mus musculus Bmp8a gene Proteins 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 claims 1
- 229960005069 calcium Drugs 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims 1
- ROPDWRCJTIRLTR-UHFFFAOYSA-L calcium metaphosphate Chemical compound [Ca+2].[O-]P(=O)=O.[O-]P(=O)=O ROPDWRCJTIRLTR-UHFFFAOYSA-L 0.000 claims 1
- 229940043256 calcium pyrophosphate Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- KBQIPTXDQGPPIO-UHFFFAOYSA-K heptacalcium;phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O KBQIPTXDQGPPIO-UHFFFAOYSA-K 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 239000011147 inorganic material Substances 0.000 claims 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims 1
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001009 osteoporotic effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016101062A JP2016209599A (ja) | 2016-05-20 | 2016-05-20 | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016101062A JP2016209599A (ja) | 2016-05-20 | 2016-05-20 | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505170A Division JP6324653B2 (ja) | 2008-04-15 | 2009-04-15 | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016209599A JP2016209599A (ja) | 2016-12-15 |
| JP2016209599A5 true JP2016209599A5 (enExample) | 2017-04-27 |
Family
ID=57549189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016101062A Ceased JP2016209599A (ja) | 2016-05-20 | 2016-05-20 | リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ） |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2016209599A (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7541280B2 (ja) * | 2019-08-27 | 2024-08-28 | 邦夫 石川 | 医療用炭酸カルシウム組成物、および関連医療用組成物、ならびにこれらの製造方法 |
| CN113769160A (zh) * | 2021-08-23 | 2021-12-10 | 广州润虹医药科技股份有限公司 | 一种温敏性微球及其即用型温敏性磷酸钙骨水泥 |
| CN113769159A (zh) * | 2021-08-23 | 2021-12-10 | 广州润虹医药科技股份有限公司 | 一种无水状态磷酸钙骨水泥及其制备方法 |
| CN113769173B (zh) * | 2021-10-26 | 2022-09-27 | 南充市中心医院 | 一种空心磷酸钙微球/丙三醇改性pmma骨水泥及其制备方法 |
| CN114209879B (zh) * | 2021-12-28 | 2022-10-14 | 北京科技大学 | 一种复合骨水泥材料及其制备方法 |
| CN120860314B (zh) * | 2025-09-22 | 2025-12-09 | 湖北双星药业股份有限公司 | 一种骨科修复用骨水泥及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69729647T2 (de) * | 1996-10-16 | 2005-07-07 | Etex Corp., Cambridge | Verfahren zur Herstellung von wenigkristallinem Calciumphosphat und Verfahren zu dessen Verwendung |
| US6840961B2 (en) * | 2001-12-21 | 2005-01-11 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| CA2521623C (en) * | 2003-04-11 | 2015-03-17 | Etex Corporation | Osteoinductive bone material |
| US8147860B2 (en) * | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
| WO2009032173A1 (en) * | 2007-08-29 | 2009-03-12 | Etex Corporation | Bone cement mixing and delivery system and methods of use thereof |
-
2016
- 2016-05-20 JP JP2016101062A patent/JP2016209599A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zimmermann et al. | Allograft bone matrix versus synthetic bone graft substitutes | |
| Sallent et al. | The few who made it: commercially and clinically successful innovative bone grafts | |
| Szpalski et al. | Applications of calcium phosphate-based cancellous bone void fillers in trauma surgery | |
| Moreau et al. | Mesenchymal stem cell proliferation and differentiation on an injectable calcium phosphate–chitosan composite scaffold | |
| Bhatt et al. | Bone graft substitutes | |
| US8048857B2 (en) | Flowable carrier compositions and methods of use | |
| CN105013017B (zh) | 一种微创骨科植入组合物 | |
| WO2012060991A4 (en) | Osteoinductive bone graft injectable cement | |
| NO333548B1 (no) | Sammensetning for behandling av et pattedyr med en bendeffekt og anvendelse derav. | |
| CN102065914A (zh) | 使用磷酸钙组合的骨接合剂的脊椎骨最小侵入性治疗(mitv) | |
| JP2010512974A5 (enExample) | ||
| JP2007533376A (ja) | 遅延凝固リン酸カルシウムペースト | |
| Chen et al. | Recent progress in injectable bone repair materials research | |
| McDermott et al. | Influence of structural load-bearing scaffolds on mechanical load-and BMP-2-mediated bone regeneration | |
| US20200009294A1 (en) | Process for instant nanoporous bioartificial bone tissue composite engineering | |
| Lou et al. | The effects of nano-hydroxyapatite/polyamide 66 scaffold on dog femoral head osteonecrosis model: a preclinical study | |
| Cornell | Osteobiologics. | |
| Chen et al. | Calcium phosphate bone cements: their development and clinical applications | |
| Markov et al. | Osteoplastic biomaterials from organic and mineral components of the bone matrix: a literature review | |
| Milner et al. | Stem cell–based therapies for bone repair | |
| Van de Watering et al. | Biodegradation of calcium phosphate cement composites | |
| CN111012952B (zh) | 一种椎体强化磷酸钙骨水泥及其制备方法 | |
| Schmidmaier et al. | Selection of graft expanders for the second stage of the induced membrane technique | |
| WO2008057860A2 (en) | Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device | |
| Telle | Bone cements in TTCP, DCPA, β-TCP and PHA system |